Jun. 5 at 3:29 AM
$ABCL if you missed the call it further went into detail about the better outlook on safety and potential increase in efficacy compared to competitors. Posed the ideas of using 635 for oncology induced hot flashes. Spoke again on trying to find a partnering company for 575 or ending the progress at phase 1. Blockbuster potential with what they think for VMS related to menopause could reach
$300 million in sales annually at lower projection. All signs support good readouts and strong future.
